Articles tagged with: Pomalidomide
In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treatment of multiple myeloma.
In their article, the experts discuss newer therapies that appear to be promising in clinical and preclinical studies.
According to the physicians, combination therapies that specifically target a patient’s genetic form of the disease will be required for long-term disease control and ultimately a cure.
Some Historical Perspective
In their review article, Drs. …
One of the advantages of living in the U.S. northeast is the chance to experience the change of the seasons. This year, the arrival of spring coincided with a new medical regimen for me and what has seemed like a rebirth of my own life.
As I described in my April column, this past winter was the season of my discontent. In less than three months, I experienced two bouts of pneumonia. I was at the hospital at least once a week, and I had near constant gastric distress. …
The American Society of Clinical Oncology will hold its 49th annual meeting May 31 through June 4 in Chicago.
Similar to previous years, more than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Building Bridges to Conquer Cancer.”
During a session at the International Myeloma Workshop (IMW) held in Japan last week, Dr. Keith Stewart from the Mayo Clinic summarized the latest findings from research related to the protein cereblon and its impact on certain myeloma treatments.
Dr. Stewart reported that low levels of cereblon are associated with lower response rates and reduced survival outcomes in multiple myeloma patients treated with the immunomodulatory agents Revlimid (lenalidomide), thalidomide (Thalomid), and Pomalyst (pomalidomide).
He explained that, with further investigation, these findings may eventually help physicians …
A sub-analysis of recent Phase 2 clinical trial results indicates that Pomalyst in combination with low-dose dexamethasone is effective and safe in multiple myeloma patients with high-risk chromosomal abnormalities who did not respond to prior therapy.
The findings were presented by Dr. Paul Richardson of the Dana-Farber Cancer Institute in Boston at the International Myeloma Workshop (IMW) in Kyoto, Japan, this past Sunday.
In the new analysis, high-risk patients were defined as those with a deletion in chromosome 17 (del17p) or the translocation t(4;14).
Although the response rates were lower and survival …